Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Qayed, Muna  [Clear All Filters]
2015
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, et al. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.
2018
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
2019
Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Díaz MÁngel, Chhabra S, Cerny J, Copelan E, et al. Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
2020
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
2021
Qayed M, Watkins B, Gillespie S, Bratrude B, Betz KM, Choi SWon, Davis JH, Duncan C, Giller RH, Grimley M, et al. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2021.
Zewde MGetachew, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, et al. Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
Qayed M, Michonneau D, Socié G, Waller EK. Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47.
Qayed M, Bleakley M, Shah NN. Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia. Curr Opin Hematol. 2021.
2022
Schoettler M, Stenger EO, Spencer K, Lutterman D, Rumbika S, Jones JA, Haight AE, Parikh SH, Qayed M, Watkins B, et al. Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children. Blood Adv. 2022.
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.
2023
Knight TE, Ahn KWoo, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, et al. No impact of CD34 cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant. 2023.
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano J-A, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023;65:102268.
2024
Takahashi T, Watkins B, Bratrude B, Neuberg D, Hebert K, Betz K, Yu A, Choi SW, Davis J, Duncan C, et al. The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplant Cell Ther. 2024.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Malki MMAl, Ayuk F, Bader P, Baez J, et al. A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, A Ayuk F, Aziz M, Baez J, Choe H, DeFilipp Z, et al. A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD. Transplant Cell Ther. 2024.